Hemolytic Anemia Associated Pulmonary Hypertension

Pulmonary Vascular Disease

Volumn , Issue , 2006, Pages 170-187

  Machado, Roberto F ^a   Gladwin, Mark T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847298781     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-2246-6.50018-3     Document Type: Chapter

References (142)

1. GR Serjeant (1997) Sickle-cell disease. Lancet 350 725-730.
2. MJ Stuart and RL Nagel (2004) Sickle-cell disease. Lancet 364 1343-1360.
3. DJ Weatherall (1997) The thalassaemias. BMJ 314 1675-1678.
4. RP Rother, L Bell, P Hillmen, et al. (2005) The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 293 1653-1662.
5. FS Collins and EP Orringer (1982) Pulmonary hypertension and cor pulmonale in the sickle hemoglo-binopathies. Am J Med 73 814-821.
6. D Powars, JA Weidman, T Odom-Maryon, et al. (1988) Sickle cell chronic lung disease: Prior morbidity and the risk of pulmonary failure. Medicine 67 66-76.
7. LL Sutton, O Castro, DJ Cross, et al. (1994) Pulmonary hypertension in sickle cell disease. Am J Cardiol 74 626-628.
8. O Castro (1996) Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am 10 1289-1303.
9. BE Simmons, V Santhanam, A Castaner, et al. (1988) Sickle cell heart disease. Two-dimensional echo and Doppler ultrasonographic findings in the hearts of adult patients with sickle cell anemia. Arch Intern Med 148 1526-1528.
10. SE Aboubakr, R Girgis and P Swerldow (1999) Pulmonary hypertension in sickle cell disease. Am J Respir Crit Care Med 160 A144. (abstract)
11. AK Haque, S Gokhale, BA Rampy, et al. (2002) Pulmonary hypertension in sickle cell hemoglobinopathy: A clinicopathologic study of 20 cases. Hum Pathol 33 1037-1043.
12. O Castro, M Hoque and BD Brown (2003) Pulmonary hypertension in sickle cell disease: Cardiac catheterization results and survival. Blood 101 1257-1261.
13. R Boussaada, K Boubaker, S Mourali, et al. (2004) [Pulmonary hypertension in sickle cell anemia. A case report.]. Tunis Med 82(Suppl 1), 180-184.
14. MT Gladwin, V Sachdev, ML Jison, et al. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350 886-895.
15. KI Ataga, N Sood, G De Gent, et al. (2004) Pulmonary hypertension in sickle cell disease. Am J Med 117 665-669.
16. TJ Wu, CD Tseng, YZ Tseng, et al. (1986) [A case of β-thalassemia major with mediastinal hematopoi-etic tumor and pulmonary hypertension.]. Taiwan Yi Xue Hui Za Zhi 85 315-320.
17. A Aessopos, G Stamatelos, V Skoumas, et al. (1995) Pulmonary hypertension and right heart failure in patients with β-thalassemia intermedia. Chest 107 50-53.
18. ZD Du, N Roguin, E Milgram, et al. (1997) Pulmonary hypertension in patients with thalassemia major. Am Heart J 134 532-537.
19. P Jootar and S Fucharoen (1990) Cardiac involvement in β-thalassemia/hemoglobin E disease: Clinical and hemodynamic findings. Southeast Asian J Trap Med Public Health 21 269-273.
20. D Grisaru, EA Rachmilewitz, M Mosseri, et al. (1990) Cardiopulmonary assessment in β-thalassemia major. Chest 98 1138-1142.
21. M Finazzo, M Midiri, P D'Angelo, et al. (1998) [The heart of the patient with β thalassemia major. Study with magnetic resonance.]. Radiol Med (Torino) 96 462-465.
22. G Derchi, A Fonti, GL Forni, et al. (1999) Pulmonary hypertension in patients with thalassemia major. Am Heart J 138 384.
23. A Aessopos, D Farmakis, M Karagiorga, et al. (2001) Cardiac involvement in thalassemia intermedia: A multicenter study. Blood 97 3411-3416.
24. E Zakynthinos, T Vassilakopoulos, P Kaltsas, et al. (2001) Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax 56 737-739.
25. V Atichartakarn, K Likittanasombat, S Chuncharunee, et al. (2003) Pulmonary arterial hypertension in previously splenectomized patients with β-thalassemic disorders. Hit J Hematol 78 139-145.
26. T Uchida, T Miyake, M Matsuno, et al. (1998) Fatal pulmonary thromboembolism in a patient with paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki 39 150-152.
27. PG Heller, AR Grinberg, M Lencioni, et al. (1992) Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest 102 642-643.
28. D Verresen, W De Backer, J Van Meerbeeck, et al. (1991) Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J 4 629-631.
29. GW Stewart, JA Amess, SW Eber, et al. (1996) Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol 93 303-310.
30. JE Hayag-Barin, RE Smith and FC Tucker Jr (1998) Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: A case report and review of the literature. Am J Hematol 57 82-84.
31. X Jais, SJ Till, T Cynober, et al. (2003) An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: Gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. Hemoglobin 27 139-147.
32. B Murali, A Drain, D Seller, et al. (2003) Pulmonary throm-boendarterectomy in a case of hereditary stomatocytosis. Br J Anaesth 91 739-741.
33. DL Jardine and AD Laing (2004) Delayed pulmonary hypertension following splenectomy for congenital spherocytosis. Intern Med J 34 214-216.
34. ID Stuard, RS Heusinkveld and AJ Moss (1972) Micro-angiopathic hemolytic anemia and thrombo-cytopenia in primary pulmonary hypertension. N Engl J Med 287 869-870.
35. JT McCarthy and BA Staats (1986) Pulmonary hypertension, hemolytic anemia, and renal failure. A mitomycin-associated syndrome. Chest 89 608-611.
36. SJ Jubelirer (1991) Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia. Arch Intern Med 151 1221-1223.
37. H Suzuki, M Nakasato, S Sato, et al. (1997) Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension. Tohoku J Exp Med 181 379-384.
38. P Labrune, J Zittoun, I Duvaltier, et al. (1999) Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Eur J Pediatr 158 734-739.
39. EG Fischer, JM Marek, A Morris, et al. (2000) Cholesterol granulomas of the lungs associated with micro-angiopathic hemolytic anemia and thrombocytopenia in pulmonary hypertension. Arch Pathol Lab Med 124 1813-1815.
40. R Alvarez Navascues and R Marin (2001) [Severe maternal complications associated with pre-eclampsia: An almost forgotten pathology?]. Nefrologia 21 565-573.
41. R Chou and TG DeLoughery (2001) Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency. Am J Hematol 67 197-199.
42. FW Huchzermeyer (1988) Avian pulmonary hypertension syndrome. IV. Increased right ventricular mass in turkeys experimentally infected with. Plasmodium durae. Onderstepoort J Vet Res 55 107-108.
43. JM Saissy, B Rouvin and P Koulmann (2003) [Severe malaria in intensive care units in 2003.]. Med Trap (Mars) 63 258-266.
44. E Strauss, LC Da Costa Gayotto, R Antonelli, et al. (1986) Systemic surgical shunts and splenomegaly as causes of haemolysis in portal hypertension in man-sonic schistosomiasis. Evaluation through serum levels of haptoglobin, hemopexin and bilirubins. J Hepatol 2 340-350.
45. R de Cleva, P Herman, V Pugliese, et al. (2003) Prevalence of pulmonary hypertension in patients with hepa-tosplenic Mansonic schistosomiasis—prospective study. Hepatogastroenterology 50 2028-2030.
46. K Kyllonen, T Mattila, M Hartikainen, et al. (1976) Mitral valve replacement with ball and tilting disc valve prosthesis. A clinical and haemodynamic study. Scand J Thorac Cardiovasc Surg 10 15-20.
47. H Iwaki, S Kuraoka and S Tatebe (2003) [Hemolytic anemia due to aortic valve regurgitation after mitral valve replacement.]. Kyobu GeL 56 124-128.
48. AO Chukwuemeka, MR Turtle, UH Trivedi, et al. (2000) A clinical evaluation of platelet function, haemolysis and oxygen transfer during cardiopulmonary bypass comparing the Quantum HF-6700 to the HF-5700 hollow fibre membrane oxygenator. Perfusión 15 479-484.
49. A Pierangeli, V Masieri, F Bruzzi, et al. (2001) Haemolysis during cardiopulmonary bypass: How to reduce the free haemoglobin by managing the suctioned blood separately. Perfusión 16 519-524.
50. R Gerrah, Y Shargal and A Elami (2003) Impaired oxygenation and increased hemolysis after cardiopulmonary bypass in patients with glucose-6-phosphate dehy-drogenase deficiency. Ann Thorac Surg 76 523-527.
51. P Philippidis, JC Mason, BJ Evans, et al. (2004) Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: Antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94 119-126.
52. Y Takami, K Makinouchi, T Nakazawa, et al. (1996) Hemolytic characteristics of a pivot bearing supported Gyro centrifugal pump (C1E3) simulating various clinical applications. Artif Organs 20 1042-1049.
53. LM De Castro, JC Jonassiant, FL Graham, et al. (2004) Pulmonary hypertension in SS, SC and Sβ tha-lassemia: Prevalence, associated clinical syndromes, and mortality. Blood 104 462a.
54. K Ataga, S Jones, O Olajide, et al. (2004) The relationship of pulmonary hypertension and survival in sickle cell disease. Blood 104 463a.
55. ML Jison and MT Gladwin (2003) Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Respir Crit Care Med 168 3-4.
56. CD Reiter, X Wang, JE Tanus-Santos, et al. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8 1383-1389.
57. PC Minneci, KJ Deans, H Zhi, et al. (2005) Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest 115 3409-3417.
58. MT Gladwin, JH Crawford and RP Patel (2004) The biochemistry of nitric oxide, nitrite, and hemoglobin: Role in blood flow regulation. Free Radie Biol Med 36 707-717.
59. MT Gladwin, JR Lancaster Jr, BA Freeman, et al. (2003) Nitric oxide's reactions with hemoglobin: A view through the SNO-storm. Nat Med 9 496-500.
60. AN Schechter and MT Gladwin (2003) Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 348 1483-1485.
61. MT Gladwin, AN Schechter, JH Shelhamer, et al. (1999) Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest 104 937-945.
62. M Aslan, TM Ryan, B Adler, et al. (2001) Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Nati Acad Sci U S A 98 15215-15220.
63. M Aslan, TM Ryan, TM Townes, et al. (2003) Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J Biol Chem 278 4194-4204.
64. RT Eberhardt, L McMahon, SJ Duffy, et al. (2003) Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol 74 104-111.
65. KA Nath, ZS Katusic and MT Gladwin (2004) The perfusion paradox and vascular instability in sickle cell disease. Microcirculation 11 179-193.
66. CD Reiter and MT Gladwin (2003) An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 10 99-107.
67. MT Gladwin, AN Schechter, FP Ognibene, et al. (2003) Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 107 271-278.
68. RP Hebbel (1985) Auto-oxidation and a membrane-associated “Fenton reagent”: A possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 14 129-140.
69. BN Setty, MJ Stuart, C Dampier, et al. (2003) Hypoxaemia in sickle cell disease: Biomarker modulation and relevance to pathophysiology. Lancet 362 1450-1455.
70. S Ergul, CY Brunson, J Hutchinson, et al. (2004) Vasoactive factors in sickle cell disease: In vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol 76 245-251.
71. E Graido-Gonzalez, JC Doherty, EW Bergreen, et al. (1998) Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 92 2551-2555.
72. M Phelan, SP Perrine, M Brauer, et al. (1995) Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 96 1145-1151.
73. YT Shiu, LV McIntire and MM Udden (2002) Sickle erythrocytes increase prostacyclin and endothelin-1 production by cultured human endothelial cells under flow conditions. Eur J Haematol 68 163-169.
74. A Rivera, P Jarolim and C Brugnara (2002) Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood 99 357-603.
75. D Keh, M Gerlach, I Kurer, et al. (1996) Reduction of platelet trapping in membrane oxygenators by transmembraneous application of gaseous nitric oxide. Int J Artif Organs 19 291-293.
76. AD Michelson, SE Benoit, MI Furman, et al. (1996) Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am J Physiol 270 H1640-H1648.
77. MW Radomski, RM Palmer and S Moncada (1987) Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2 1057-1058.
78. MW Radomski, P Vallance, G Whitley, et al. (1993) Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 27 1380-1382.
79. MT Gladwin and GP Rodgers (2000) Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. Lancet 355 1476-1478.
80. E Azizi, Y Dror and K Wallis (1970) Arginase activity in erythrocytes of healthy and ill children. Clin Chim Acta 28 391-396.
81. F Belfiore (1964) [Enzymatic activities of the blood serum in thalassemia and in thalassodrepanocytosis.]. Riforma Med 78 1052-1055.
82. CR Morris, SM Morris Jr, W Hagar, et al. (2003) Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 168 63-69.
83. JJ Schnog, EH Jager, FP van der Dijs, et al. (2004) Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol 83 371-375.
84. CR Morris, GJ Kato, M Poljakovic, et al. (2005) Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. Jama 294 81-90.
85. MM Hoeper, J Niedermeyer, F Hoffmeyer, et al. (1999) Pulmonary hypertension after splenectomy? Ann Intern Med 130 506-509.
86. V Atichartakarn, P Angchaisuksiri, K Aryurachai, et al. (2003) In vivo platelet activation and hyperaggregation in hemoglobin E/β-thalassemia: A consequence of splenectomy. Int J Hematol 77 299-303.
87. A Kisanuki, S Kietthubthew, Y Asada, et al. (1997) Intravenous injection of sonicated blood induces pulmonary microthromboembolism in rabbits with ligation of the splenic artery. Thromb Res 85 95-103.
88. M Westerman, A Pizzey, J Hirschman, et al. (2004) Plasma “free” Hb is related to red cell derived vesicle numbers in sickle cell anemia and thalassemia intermedia: Implications for nitric oxide (NO) scavenging and pulmonary hypertension. Blood 104 465a.
89. V Atichartakarn, P Angchaisuksiri, K Aryurachai, et al. (2002) Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/β-thalassaemic patients. Br J Haematol 118 893-898.
90. V Carnelli, E D'Angelo, M Pecchiari, et al. (2003) Pulmonary dysfunction in transfusion-dependent patients with thalassemia major. Am J Respir Crit Care Med 168 180-184.
91. DY Tai, YT Wang, J Lou, et al. (1996) Lungs in thalassaemia major patients receiving regular transfusion. Eur Respir J 9 1389-1394.
92. SI Berney, CD Ridler, AD Stephens, et al. (1992) Enhanced platelet reactivity and hypercoagulability in the steady state of sickle cell anaemia. Am J Hematol 40 290-294.
93. MA el-Hazmi, AS Warsy and H Bahakim (1993) Blood proteins C and S in sickle cell disease. Acta Haematol 90 114-119.
94. D Hagger, S Wolff, J Owen, et al. (1995) Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis 6 93-99.
95. J Kurantsin-Mills, FA Ofosu, TK Safa, et al. (1992) Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 81 539-544.
96. A Marfaing-Koka, C Boyer-Neumann, M Wolf, et al. (1993) Decreased protein S activity in sickle cell disease. Nouv Rev Fr Hematol 35 425-430.
97. M Peters, BE Plaat, H ten Cate, et al. (1994) Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 71 169-172.
98. AS Shet, O Aras, K Gupta, et al. (2003) Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 102 2678-2683.
99. MO Adedeji, J Cespedes, K Allen, et al. (2001) Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 125 1436-1441.
100. EA Manci, DE Culberson, YM Yang, et al. (2003) Causes of death in sickle cell disease: An autopsy study. Br J Haematol 123 359-365.
101. EP Vichinsky (2004) Pulmonary hypertension in sickle cell disease. N Engl J Med 350 857-859.
102. A Taher, Y Abou-Mourad, A Abchee, et al. (2002) Pulmonary thromboembolism in β-thalassemia intermedia: Are we aware of this complication? Hemoglobin 26 107-112.
103. T Uchida, T Miyake, M Matsuno, et al. (1998) [Fatal pulmonary thromboembolism in a patient with paroxysmal nocturnal hemoglobinuria.]. Rinsho Ketsueki 39 150-152.
104. RF Machado, SE Martyr, A Anthi, et al. (2004) Pulmonary hypertension in sickle cell disease: Cardiopulmonary evaluation and response to chronic phos-phodiesterase 5 inhibitor therapy. Blood 104 71a.
105. RJ Barst, D Langleben, A Frost, et al. (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 441-447.
106. GJ Kato, S Martyr, RF Machado, et al. (2004) Acute and chronic pulmonary hypertension in patients with sickle cell disease. Blood 104 464a.
107. RJ Barst, M McGoon, A Torbicki, et al. (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S), 40S-47S.
108. M McGoon, D Gutterman, V Steen, et al. (2004) Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl), 14S-34S.
109. G Derchi, GL Forni, F Formisano, et al. (2005) Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglo-binopathies. Haematologica 90 452-458.
110. E Bossone, M Rubenfire, DS Bach, et al. (1999) Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: Implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 33 1662-1666.
111. AC Koumbourlis, A Hurlet-Jensen and MR Bye (1997) Lung function in infants with sickle cell disease. Pediatr Pulmonol 24 277-281.
112. AC Koumbourlis, HJ Zar, A Hurlet-Jensen, et al. (2001) Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr 138 188-192.
113. J Lonsdorfer, P Bogui, A Otayeck, et al. (1983) Cardio-respiratory adjustments in chronic sickle cell anemia. Bull Eur Physiopathol Respir 19 339-344.
114. F Santoli, F Zerah, N Vasile, et al. (1998) Pulmonary function in sickle cell disease with or without acute chest syndrome. Eur Respir J 12 1124-1129.
115. RC Young Jr, RE Rachal, CA Reindorf, et al. (1988) Lung function in sickle cell hemoglobinopathy patients compared with healthy subjects. J Nat Med Assoc 80 509-514.
116. GL Yung, RN Channick, PF Fedullo, et al. (1998) Successful pulmonary thromboendarterectomy in two patients with sickle cell disease. Am J Respir Crit Care Med 157 1690-1693.
117. RJ Castele, KP Strohl, CS Chester, et al. (1986) Oxygen saturation with sleep in patients with sickle cell disease. Arch Intern Med 146 722-725.
118. DR Hargrave, A Wade, JP Evans, et al. (2003) Nocturnal oxygen saturation and painful sickle cell crises in children. Blood 101 846-884.
119. JP Needleman, ME Franco, L Varlotta, et al. (1999) Mechanisms of nocturnal oxyhemoglobin desaturation in children and adolescents with sickle cell disease. Pediatr Pulmonol 28 418-422.
120. FJ Kirkham, DK Hewes, M Prengler, et al. (2001) Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet 357 1656-1659.
121. CT Quinn and N Ahmad (2005) Prevalence and predictors of steady state hypoxemia in sickle cell disease. Br J Haematol 131 129-134.
122. MH Steinberg, F Barton, O Castro, et al. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 289 1645-1651.
123. S Charache, ML Terrin, RD Moore, et al. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332 1317-1322.
124. RJ Adams, VC McKie, L Hsu, et al. (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339 5-11.
125. M Koshy, L Burd, D Wallace, et al. (1988) Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med 319 1447-1452.
126. CH Pegelow, RJ Adams, V McKie, et al. (1995) Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 126 896-899.
127. A Aessopos, D Farmakis, A Hatziliami, et al. (2004) Cardiac status in well-treated patients with tha-lassemia major. Eur J Haematol 73 359-366.
128. P Hillmen, C Hall, JC Marsh, et al. (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemo-globinuria. N Engl J Med 350 552-559.
129. H Frank, J Mlczoch, K Huber, et al. (1997) The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 112 714-721.
130. V Fuster, PM Steele, WD Edwards, et al. (1984) Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 70 580-587.
131. S Rich, E Kaufmann and PS Levy (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 76-81.
132. K Ohene-Frempong, SJ Weiner, LA Sleeper, et al. (1998) Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 91 288-294.
133. AR Cohen, R Galanello, DJ Pennell, et al. (2004) Thalassemia. Hematology (Am Soc Hematol Educ Program) 14-34.
134. DB Badesch, VV McLaughlin, M Delcroix, et al. (2004) Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S), 56S-61S.
135. RN Channick, O Sitbon, RJ Barst, et al. (2004) Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S), 62S-67S.
136. HA Ghofrani, J Pepke-Zaba, JA Barbera, et al. (2004) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S), 68S-72S.
137. N Galie, HA Ghofrani, A Torbicki, et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 2148-2157.
138. RN Channick, JW Newhart, FW Johnson, et al. (1996) Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests. Chest 109 1545-1549.
139. R Littera, G La Nasa, G Derchi, et al. (2002) Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 100 1516-1517.
140. RF Machado, S Martyr, GJ Kato, et al. (2005) Sildenafil therapy in patients with sickle disease and pulmonary hypertension. Br J Haematol 130 445-453.
141. RF Machado and MT Gladwin (2005) Chronic sickle cell lung disease: New insights into the diagnosis, patho-genesis and treatment of pulmonary hypertension. Br J Haematol 129 449-464.
142. EE Lin, MT Gladwin and RF Machado (2005) Pulmonary hypertension in patients with hemoglo-binopathies: Could a mechanism for dysfunction provide an avenue for novel therapeutics? Haematologica 90 441-444.